{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:00:53Z","timestamp":1787871653521,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U01CA274298"],"award-info":[{"award-number":["U01CA274298"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA199064"],"award-info":[{"award-number":["R01CA199064"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA199064"],"award-info":[{"award-number":["R01CA199064"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01228-6","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:45:57Z","timestamp":1766270757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cross-platform comparison of gene expression-based cancer molecular subtyping reveals discrepancies with exome capture methods"],"prefix":"10.1038","volume":"10","author":[{"given":"Jaewon J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Aldakkak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley B.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam Z.","family":"Thalji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlu L.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkut H.","family":"Borazanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim U.","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen Jen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"1228_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101063","volume":"14","author":"JT Jorgensen","year":"2021","unstructured":"Jorgensen, J. T. The current landscape of the FDA approved companion diagnostics. Transl. Oncol. 14, 101063 (2021).","journal-title":"Transl. Oncol."},{"key":"1228_CR2","unstructured":"The Pew Charitable Trusts. The Role of Lab-Developed Tests in the In Vitro Diagnostics Market. https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/reports\/2021\/10\/the-role-of-lab-developed-tests-in-the-in-vitro-diagnostics-market (2021)."},{"key":"1228_CR3","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.18632\/oncotarget.26797","volume":"10","author":"N Beaubier","year":"2019","unstructured":"Beaubier, N. et al. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget 10, 2384\u20132396 (2019).","journal-title":"Oncotarget"},{"key":"1228_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00197","volume":"9","author":"S Wenric","year":"2025","unstructured":"Wenric, S. et al. Real-world validation of the purity independent subtyping of tumors classifier for informing therapy selection in pancreatic ductal adenocarcinoma. JCO Precis. Oncol. 9, e2500197 (2025).","journal-title":"JCO Precis. Oncol."},{"key":"1228_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1078-0432.CCR-19-1467","volume":"26","author":"NU Rashid","year":"2020","unstructured":"Rashid, N. U. et al. Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. Clin. Cancer Res. 26, 82\u201392 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1228_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jmoldx.2024.07.002","volume":"26","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Purity Independent Subtyping of Tumors (PurIST) Pancreatic Cancer Classifier: Analytic Validation of a 16-RNA Expression Signature Distinguishing Basal and Classical Subtypes. J. Mol. Diagn. 26, 962\u2013970 (2024).","journal-title":"J. Mol. Diagn."},{"key":"1228_CR7","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178 (2015).","journal-title":"Nat. Genet."},{"key":"1228_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ccell.2018.12.010","volume":"35","author":"AA Connor","year":"2019","unstructured":"Connor, A. A. et al. Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases. Cancer Cell 35, 267\u2013282.e267 (2019).","journal-title":"Cancer Cell"},{"key":"1228_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231\u2013240 (2020).","journal-title":"Nat. Genet."},{"key":"1228_CR10","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1228_CR11","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019Kane","year":"2020","unstructured":"O\u2019Kane, G. M. et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin. Cancer Res. 26, 4901\u20134910 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1228_CR12","doi-asserted-by":"publisher","first-page":"LBA4004","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4004","volume":"42","author":"JJ Knox","year":"2024","unstructured":"Knox, J. J. et al. Early results of the PASS-01 trial: pancreatic adenocarcinoma signature stratification for treatment-01. J. Clin. Oncol. 42, LBA4004\u2013LBA4004 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1228_CR13","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1158\/1078-0432.CCR-24-1164","volume":"30","author":"H Singh","year":"2024","unstructured":"Singh, H. et al. Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer. Clin. Cancer Res. 30, 4932\u20134942 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1228_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening, T. M. et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 17, 651\u2013662 (2016).","journal-title":"Lancet Oncol."},{"key":"1228_CR15","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly, J. et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 14, 2135\u20132161 (2024).","journal-title":"Cancer Discov."},{"key":"1228_CR16","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1158\/2159-8290.CD-24-0740","volume":"14","author":"A Singhal","year":"2024","unstructured":"Singhal, A. et al. A classical epithelial state drives acute resistance to kras inhibition in pancreatic cancer. Cancer Discov. 14, 2122\u20132134 (2024).","journal-title":"Cancer Discov."},{"key":"1228_CR17","doi-asserted-by":"crossref","unstructured":"Xu, Y. et al. Tumor-intrinsic kinome landscape of pancreatic cancer reveals new therapeutic approaches. Cancer Discov. 15, 346\u2013362 (2024).","DOI":"10.1158\/2159-8290.CD-23-1480"},{"key":"1228_CR18","doi-asserted-by":"crossref","unstructured":"Andrews, H. S. et al. Analysis of 20 independently performed assays to measure Homologous Recombination Deficiency (HRD) in ovarian cancer: findings from the friends\u2019 HRD Harmonization Project. JCO Onco. Adv. 1, e2400042 (2024).","DOI":"10.1200\/OA-24-00042"},{"key":"1228_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmoldx.2024.05.002","volume":"26","author":"LV Furtado","year":"2024","unstructured":"Furtado, L. V. et al. Recommendations for tumor mutational burden assay validation and reporting: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer. J. Mol. Diagn. 26, 653\u2013668 (2024).","journal-title":"J. Mol. Diagn."},{"key":"1228_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis, J. R. & Koch, G. G. The measurement of observer agreement for categorical data. Biometrics 33, 159\u2013174 (1977).","journal-title":"Biometrics"},{"key":"1228_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"1228_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"1228_CR23","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1158\/1078-0432.CCR-20-3925","volume":"27","author":"JJ Lee","year":"2021","unstructured":"Lee, J. J. et al. Elucidation of tumor-stromal heterogeneity and the ligand-receptor interactome by single-cell transcriptomics in real-world pancreatic cancer biopsies. Clin. Cancer Res. 27, 5912\u20135921 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1228_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/0008-5472.CAN-22-3050","volume":"83","author":"HL Williams","year":"2023","unstructured":"Williams, H. L. et al. Spatially resolved single-cell assessment of pancreatic cancer expression subtypes reveals co-expressor phenotypes and extensive intratumoral heterogeneity. Cancer Res. 83, 441\u2013455 (2023).","journal-title":"Cancer Res."},{"key":"1228_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41586-025-08927-x","volume":"642","author":"G Pei","year":"2025","unstructured":"Pei, G. et al. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Nature 642, 212\u2013221 (2025).","journal-title":"Nature"},{"key":"1228_CR26","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"1228_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12517-7","volume":"10","author":"XL Peng","year":"2019","unstructured":"Peng, X. L., Moffitt, R. A., Torphy, R. J., Volmar, K. E. & Yeh, J. J. De novo compartment deconvolution and weight estimation of tumor samples using DECODER. Nat. Commun. 10, 4729 (2019).","journal-title":"Nat. Commun."},{"key":"1228_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60808-z","volume":"16","author":"JJ Knox","year":"2025","unstructured":"Knox, J. J. et al. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Nat. Commun. 16, 5919 (2025).","journal-title":"Nat. Commun."},{"key":"1228_CR29","doi-asserted-by":"crossref","unstructured":"Knox, J. J. et al. PASS-01: randomized phase II trial of modified FOLFIRINOX versus gemcitabine\/Nab-Paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer. J. Clin. Oncol. 43, 3355\u20133368 (2025).","DOI":"10.1200\/JCO-25-00436"},{"key":"1228_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0129-6","volume":"8","author":"B Wallden","year":"2015","unstructured":"Wallden, B. et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genom. 8, 54 (2015).","journal-title":"BMC Med Genom."},{"key":"1228_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09669-z","volume":"22","author":"BD Leibowitz","year":"2022","unstructured":"Leibowitz, B. D. et al. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. BMC Cancer 22, 587 (2022).","journal-title":"BMC Cancer"},{"key":"1228_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40291-023-00650-5","volume":"27","author":"J Michuda","year":"2023","unstructured":"Michuda, J. et al. Validation of a transcriptome-based assay for classifying cancers of unknown primary origin. Mol. Diagn. Ther. 27, 499\u2013511 (2023).","journal-title":"Mol. Diagn. Ther."},{"key":"1228_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01228-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01228-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01228-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T21:01:53Z","timestamp":1768942913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01228-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01228-6","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PurIST was licensed to GeneCentric Therapeutics and subsequently licensed to Tempus AI. Neither GeneCentric nor Tempus was involved in the design of this study. J.J.Y. and N.U.R. are patent holders of PurIST (WO2020205993A1). E.H.B. has consulting or advisory roles at NanOlogy, BPGbio, ClearNote Health, Merus, VCN Biosciences, Corcept Therapeutics, and Arcus Biosciences, and HonorHealth Research Institute receives research funding from Bristol-Myers Squibb, Pharmacyclics, Idera, Daiichi Sankyo, Minneamrita Therapeutics, Lilly, Merck, Helix, BioNTech AG, Corcept Therapeutics, and Biosplice. Remaining authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}